BioCentury | Oct 29, 2012
Company News

Igan Biosciences, Shire deal

Igan granted Shire exclusive, worldwide rights to develop and commercialize preclinical IgA protease to treat IgA nephropathy, a rare kidney disorder. Geller Biopharm Inc. advised Igan. Igan declined to provide details, while Shire could not...
Items per page:
1 - 1 of 1
BioCentury | Oct 29, 2012
Company News

Igan Biosciences, Shire deal

Igan granted Shire exclusive, worldwide rights to develop and commercialize preclinical IgA protease to treat IgA nephropathy, a rare kidney disorder. Geller Biopharm Inc. advised Igan. Igan declined to provide details, while Shire could not...
Items per page:
1 - 1 of 1